A Phase Ib Study of the Safety and Pharmacology of Atezolizumab Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Trial Profile

A Phase Ib Study of the Safety and Pharmacology of Atezolizumab Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Cobimetinib (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 06 Jun 2017 Updated safety and clinical activity results (Data cut off: 12 Oct, 2016) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 03 Jun 2017 Updated safety and clinical activity results from this trial will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting according to a Roche media release.
    • 09 May 2017 Planned End Date changed from 1 Aug 2017 to 23 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top